Core B is the Nuclear Medicine Core and is responsible for the following: 1. Preparation of trace-labeled [131]l-BC8 Ab, [111]In labeled DOTA-BC8 Ab, [86]Y labeled DOTA-BC8 Ab, [111]In labeled DOTA-1F5 Ab, and [111]In labeled DOTA-biotin for evaluation of biodistributions in patients with AML, ALL, MDS, and NHL. (Projects 1, 2 and 3) 2. Performance of serial quantitative gamma camera imaging a. Performance of planar imaging in multiple projections in leukemia and lymphoma patients infused with trace-labeled [131]l-anti-CD45 (BCS), [111]In-DOTA BC8, or [111]In labeled DOTA-anti CD20 (1F5) antibodies; or with BC8-streptavidin (BC8-SA) conjugate followed by [111]In labeled DOTA-biotin (Projects 1, 2 and 3) b. Performance of SPECT imaging in one or more body regions for 3D reconstruction of uptake in normal organs and tumor to estimate or normalize uptake for dosimetry evaluation in patients with measurable lymphoma (one SPECT scan per patient performed 24 hours after infusion). (Projects 2 &3) c. Performance of sequential biodistribution and dosimetry studies comparing: i. [111]In labeled DOTA-anfi-CD45 (BCS) and [111]In labeled DOTA-anti CD20 (1F5) antibodies in patients with NHL (Project 2) ii. [111]In labeled DOTA-anti-CD45 (BCS) and [86]Y labeled DOTA BCS Ab in patients with NHL (Project 2) iii. [111]In labeled DOTA-anfi-CD45 (BCS) Ab vs BCS-SA followed by [111]In labeled DOTA biotin in patients with leukemia and lymphoma. (Project 3) 3, Performance of PET imaging on days 0, 1, 2 and 3 in patients with NHL lymphoma after trace-labeled infusion of [86]Y-DOTA anti-CD 45 (BCS) Ab (Project 2) 4, Quantification of biodistribution and estimate radiation absorbed doses of [131]l-BC8, [111]In DOTA-BC8 Ab, [111]In DOTA-1F5 Ab, and [111]In labeled DOTA biotin for evaluation and treatment of patients with [131]I - or [90]Y-labeled anti-CD 45 (BC8) Ab (Projects 1 and 2) or BC8-SA followed by [90]Y labeled DOTA biotin. (Project 3) 5. Preparation and administration of therapeutic doses of [131]I or [90]Y-DOTA-BC8 antibodies and [90]Y-labeled DOTA biotin for treatment of patients with lymphoma and leukemia, (Projects 1, 2 and 3) 6. Provision of radiation safety monitoring and counseling for patients and staff. (Projects 1, 2, and 3)

Public Health Relevance

Nuclear medicine physicians on Core B attach radioactive isotopes to monoclonal antibodies and inject them into patients with leukemia, lymphoma, and myelodysplasia. Nuclear medicine imaging techniques are then used to determine if the radiolabeled antibodies target properly to tumor sites, based on dosimetry done by Dr. Darrell Fisher. If the antibodies target, the nuclear medicine physicians administer therapeutic doses of the radiolabeled antibodies to treat the cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA044991-23A1
Application #
8131415
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (J1))
Project Start
1997-05-01
Project End
2016-07-31
Budget Start
2011-08-03
Budget End
2012-07-31
Support Year
23
Fiscal Year
2011
Total Cost
$631,694
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cowan, Andrew J; Stevenson, Phillip A; Gooley, Ted A et al. (2017) Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. Br J Haematol 176:583-590
O'Steen, Shyril; Green, Damian J; Gopal, Ajay K et al. (2017) Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Res 77:3885-3893
Green, Damian J; Press, Oliver W (2017) Whither Radioimmunotherapy: To Be or Not To Be? Cancer Res 77:2191-2196
Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19
Graf, Solomon A; Gopal, Ajay K (2016) Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother 17:265-74
Cowan, Andrew J; Stevenson, Philip A; Cassaday, Ryan D et al. (2016) Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. Biol Blood Marrow Transplant 22:380-385
Orozco, Johnnie J; Kenoyer, Aimee; Balkin, Ethan R et al. (2016) Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood 127:352-9
Chen, Robert; Gopal, Ajay K; Smith, Scott E et al. (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128:1562-6
Shadman, Mazyar; Gopal, Ajay K; Kammerer, Britt et al. (2016) Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission. Leuk Lymphoma 57:572-6
Green, D J; Bensinger, W I; Holmberg, L A et al. (2016) Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 51:1330-1336

Showing the most recent 10 out of 130 publications